- ImmuCell ( NASDAQ: ICCC ) announces preliminary sales results for Q2 of $3.9M, an decrease of 15% Y/Y.
- 1H sales of $9.9M, an increase of 14% Y/Y.
-
“A material disruption in the supply to us of needed plastic parts limited our production and sales during the quarter. We had a backlog of orders worth approximately $704,000 as of June 30, 2022 that all could have been shipped to customers erasing this drop in sales for the quarter, if not for this supply disruption that we are working to resolve during the third quarter. The strategic investments we are making to incrementally expand our First Defense ® manufacturing capacity further to approximately $30 million per year during the third quarter and to approximately $35 million per year during the fourth quarter are on track. Our work to achieve regulatory approval to commercialize Re-Tain ® continues. We expect a response from the FDA during the third quarter to our submission of the final Technical Section required to complete our New Animal Drug Application, and we have submitted our responses to all of the findings from a recent pre-approval inspection by the FDA.” commented Michael F. Brigham, President and CEO.
For further details see:
ImmuCell announces preliminary 2Q sales of $3.9M